The estimated Net Worth of Robert Ora Felsch is at least 2.47 百万$ dollars as of 20 August 2024. Robert Felsch owns over 3,567 units of Ardelyx Inc stock worth over 545,698$ and over the last 2 years Robert sold ARDX stock worth over 1,922,807$.
Robert has made over 9 trades of the Ardelyx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Robert sold 3,567 units of ARDX stock worth 20,903$ on 20 August 2024.
The largest trade Robert's ever made was selling 207,988 units of Ardelyx Inc stock on 6 May 2024 worth over 1,832,374$. On average, Robert trades about 20,613 units every 65 days since 2022. As of 20 August 2024 Robert still owns at least 91,560 units of Ardelyx Inc stock.
You can see the complete history of Robert Felsch stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over 37,312,621$ worth of Ardelyx Inc stock and bought 85,247,838 units worth 820,614,871$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of 1,784,764$. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth 46,650$.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: